Sorafenib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well sorafenib works in treating patients with stage IIIB
or stage IV non-small cell lung cancer. Sorafenib may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth. It may also stop the growth of non-small
cell lung cancer by blocking blood flow to the tumor.